Carregant...
Eculizumab in atypical hemolytic uremic syndrome: strategies toward restrictive use
With the introduction of the complement C5-inhibitor eculizumab, a new era was entered for patients with atypical hemolytic uremic syndrome (aHUS). Eculizumab therapy very effectively reversed thrombotic microangiopathy and reduced mortality and morbidity. Initial guidelines suggested lifelong treat...
Guardat en:
| Publicat a: | Pediatr Nephrol |
|---|---|
| Autors principals: | , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Springer Berlin Heidelberg
2018
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6794245/ https://ncbi.nlm.nih.gov/pubmed/30402748 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00467-018-4091-3 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|